Liza Laws speaks with Nikesh Shah, VP, global head of drug safety and pharmacovigilance (PV), and Dr Siva Kumar Buddha, director of pharmacovigilance and head of signal and risk management at Indegene.
As DIA's 60th anniversary at the annual event in San Diego approaches, OSP is excited to bring you insights from Advarra, a leader in advancing clinical research.
Get ready for a big reveal at the DIA conference in San Diego as GiftHealth introduces its latest AI-enabled features designed to revolutionize patient care.
Shionogi is stepping up its game in the fight against infectious diseases by opening its first discovery lab in the US, in sunny San Diego, California.
In celebration of Clinical Trials Day last month, OSP sat down with Diane Lacroix, vice president of clinical data management at eClinical Solutions, to delve into the latest advancements and future directions in clinical trials.
In an intriguing interview with Cybin’s CEO, Doug Drysdale, OSP senior editor, Liza Laws found out how second-generation psychedelics could be the biggest breakthrough in psychiatry in 40 years.
Pam Diamond spent almost three decades practicing medicine and looking at problems in the clinical research arena before changing tack so she could make a bigger impact.
SamaCare, a leading cloud-based patient access platform for specialty medications, today announced the closure of an oversubscribed $17 million Series B investment round.
Inato, the global clinical trial marketplace, recently announced the results from a survey of clinical research sponsors and sites to find out what the frustrations were, why the disappointing outcomes were so frequent - and crucially what the sponsors...
Indica Labs, a leader in digital pathology solutions, has announced that it has received FDA clearance for its enterprise digital pathology platform, HALO AP Dx, for primary diagnosis.
Hazel Jones is the CEO at Enhanc3D Genomics. We sat down with her to discuss her leap of faith into 3D genomics, and how she is scaling the business and driving operational change.
The Global Heart Hub, an international alliance of heart patient organizations based in Ireland, has unveiled the first findings from their patient-led Insights from Patients living with Elevated Cholesterol (IPEC) data generation program.
Novigenix, a force in innovative cancer diagnostics, has announced a landmark partnership with the IMMUcan Consortium, a European leader in cancer research.
In an interesting development in the field of rare disease therapeutics, Shionogi & Co., Ltd., and Maze Therapeutics, Inc. have sealed an exclusive worldwide license agreement for MZE001, a novel therapeutic candidate aimed at tackling Pompe disease.
Neurocrine Biosciences Inc. has initiated its phase 1 clinical study, marking a significant stride in the evaluation of NBI-1117567, an investigational small molecule, oral compound developed by Nxera Pharma.
Courtney Noah works in scientific affairs at BioIVT and after an amazing biology teacher in grade nine gave her a passion for science, she then followed the same teacher through her education.
Walgreens and Boehringer Ingelheim have joined forces in a move to enhance diversity and accessibility in clinical trials, aiming to make participation more inclusive and equitable.
Clerkenwell Health is proud to announce the launch of its foundation course for Psychedelic-Assisted Therapy, a comprehensive 30-hour program that brings together leading experts in the field.
Owlstone Medical, a global leader in Breath Biopsy for early disease detection and precision medicine, has announced a funding to the tune of $6.5 million.
In the heart of Montreal sits the non-profit organization Centech, a place that supports projects and startups with high growth potential – from conception right through to commercialization, which it says is thanks to a bold, collaborative, and passionate...
Last month, OSP was excited to write about One2Treat, a progressive startup specializing in digital health solutions, which has launched a forward-thinking approach aimed at tackling key challenges in the biopharma industry.
From a child's chemistry set given to her by her grandfather to watching Open University maths programs, Karen Ooms seemed destined for a career in science.
In a remarkable development, Front Line Medical Technologies Inc., an innovator in trauma care medical devices, has announced the attainment of CE marking for its COBRA-OS (Control of Bleeding, Resuscitation, Arterial Occlusion System).
In a major partnership aimed at accelerating research into Rett syndrome, a rare neurological disorder predominantly affecting girls, digital healthcare solutions company Vivalink, has joined forces with the Rett Syndrome Research Trust (RSRT).
Oncimmune Holdings plc, a prominent autoantibody profiling company catering to the pharmaceutical and biotechnology sectors, is expanding its horizons by delving into the realm of biomarkers for age-related diseases.
At CPhI North America, Quotient Sciences is looking forward to reconnecting with its customers and giving them a preview of how we are looking to expand Translational Pharmaceutics further within the US.
Kynos Therapeutics Ltd, based in Edinburgh, UK, focuses on developing small molecule kynurenine 3-monooxygenase (KMO) inhibitors for inflammatory disorders.
In a significant development for the multiple myeloma community, Menarini Stemline UK today welcomed the final draft guidance from the National Institute for Health and Care Excellence (NICE).
Earlier this week, Charles River Laboratories International, Inc. revealed its Alternative Methods Advancement Project (AMAP), which it said is a strong initiative aimed at changing drug discovery and development by exploring alternatives to animal testing.
On Monday, OSP published a story about AstraZeneca’s latest modeling analysis which highlighted major concerns about the future of chronic kidney disease (CKD) across eight countries.
During DCAT this year, CEO Gaston Salinas from Botanical Solution Inc., (BSI), sat down with Liza Laws, the senior editor of OSP and BPR to discuss his company’s pioneering work in revolutionizing vaccine adjuvant production.
Qinecsa Solutions (Qinecsa), a lead company in technology-driven end-to-end pharmacovigilance solutions has announced its acquisition of Insife ApS (Insife), a Danish-based firm specializing in innovative pharmacovigilance platforms.
Charles River Laboratories International, Inc. has unveiled its Alternative Methods Advancement Project (AMAP), a strong initiative aimed at changing drug discovery and development by exploring alternatives to animal testing.
In a recent discussion with Jan Vertommen, vice president and head of commercial development for the small molecules division at Lonza, key insights were shared regarding the pharmaceutical industry's current landscape and future trajectory.
Within the rapidly evolving landscape of decentralized clinical trials (DCTs), one critical challenge persists: the accurate monitoring of cough symptoms.
Michael Fronstin, global head of client partnership and commercialization at the company said the combination of Oracle’s life sciences expertise and platform technology help CROs win more business and run trials more efficiently.
AstraZeneca's latest modelling analysis, IMPACT CKD, presented at the 2024 ISN World Congress of Nephrology (WCN'24) in Buenos Aires, paints a concerning picture of the future of chronic kidney disease (CKD) across eight countries.
Bio Pharma Reporter and Outsourcing Pharma is back with our latest instalment of movers and shakers - breaking down all the key pharma industry appointments that you should know about. KBI Biopharma, Veranova and Kindeva Drug Delivery are among the companies...
In a groundbreaking revelation, a study conducted by RCSI University of Medicine and Health Sciences and Children’s Health Ireland has confirmed the safety and efficacy of a Cystic Fibrosis drug in newborns as young as four weeks old.
